Key Highlights
- Morgan Stanley maintained its Overweight rating on Eli Lilly (LLY) with a $1,313 price target
- Weekly Mounjaro prescriptions reached approximately 724,500, climbing from roughly 705,300 in the previous week
- Zepbound prescriptions surged to around 598,100, rising from approximately 500,900 the week prior
- Lilly’s GLP-1 portfolio commands approximately 60% of weekly new prescription market share
- Fourth-quarter EPS reached $7.54, surpassing analyst expectations, while revenue grew 42.6% year-over-year
Eli Lilly’s leading weight-loss and diabetes medications, Mounjaro and Zepbound, demonstrated prescription volume increases during the week concluded February 27, 2026, based on IQVIA data referenced by Morgan Stanley.
Mounjaro recorded total prescriptions of approximately 724,500 for the week, climbing from about 705,300 in the preceding week. New Mounjaro prescriptions totaled roughly 361,600, compared with 352,700 the week before.
Zepbound experienced a more pronounced increase. Total prescriptions reached approximately 598,100, advancing from 500,900 during the previous week. New prescriptions climbed to 328,300 from 298,600.
Morgan Stanley maintained its Overweight designation on LLY while holding its price target at $1,313. The firm anticipates approximately 7% upside potential to its 2026 projections for both medications combined.
Combined GLP-1 prescriptions for Lilly and Novo Nordisk expanded roughly 30% year-over-year, demonstrating robust ongoing demand throughout the therapeutic category.
Lilly’s complete GLP-1 portfolio — encompassing Mounjaro, Zepbound, and Trulicity — captured approximately 60% of weekly new prescription market share, edging up from 59% the prior week.
Financial Performance and Results
LLY delivered Q4 EPS of $7.54, exceeding analyst consensus of $7.48 by $0.06. Revenue totaled $19.29 billion, significantly surpassing the $17.85 billion estimate. This represented a 42.6% increase compared to the corresponding quarter one year earlier.
The company established its FY2026 guidance at $33.50–$35.00 EPS. Net margin for the quarter reached 31.66%, while return on equity measured 102.94%.
Lilly increased its quarterly dividend to $1.73, advancing from $1.50. The annualized distribution currently stands at $6.92, yielding approximately 0.7%.
The stock began trading at $982.85 on Friday. Its 52-week range extends from $623.78 to $1,133.95. The 50-day moving average registers at $1,047.37, while the 200-day average sits at $937.23.
Wall Street Coverage and Institutional Positions
Institutional ownership of LLY currently represents 82.53%. Several firms expanded their holdings during Q3 2026, including KCM Investment Advisors, which increased its position by 14%, and M1 Capital Management, which grew its stake by 10.8%.
Integrity Advisory Solutions established a new position valued at approximately $1.07 million during the quarter.
The consensus analyst rating stands at “Moderate Buy” with an average price target of $1,229.59. Wells Fargo elevated its target to $1,280 with an Overweight rating. Jefferies increased its target to $1,300, assigning the stock a Buy rating. Royal Bank of Canada initiated coverage with an Outperform rating and a $1,250 target.
Seven analysts revised their earnings projections upward following the Q4 report.
Lilly additionally introduced its “Employer Connect” platform, created to assist employers in providing coverage for obesity treatments, including Zepbound, at a $449 single-patient KwikPen pricing option.
Orforglipron, Lilly’s oral GLP-1 candidate, outperformed oral semaglutide in a Type 2 diabetes trial across both primary and secondary endpoints.
